Neonc Technologies (NASDAQ:NTHI) CEO Amir Heshmatpour Buys 35,000 Shares of Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour bought 35,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was purchased at an average price of $3.30 per share, for a total transaction of $115,500.00. Following the completion of the acquisition, the chief executive officer owned 3,183,000 shares of the company’s stock, valued at approximately $10,503,900. This trade represents a 1.11% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Neonc Technologies Trading Down 12.4%

Shares of NASDAQ NTHI traded down $0.47 during midday trading on Tuesday, reaching $3.31. 285,988 shares of the stock were exchanged, compared to its average volume of 104,731. Neonc Technologies Holdings, Inc. has a 12 month low of $3.01 and a 12 month high of $12.99. The business has a 50-day simple moving average of $4.04 and a two-hundred day simple moving average of $5.27.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Institutional Investors Weigh In On Neonc Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Westmount Partners LLC boosted its position in Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after acquiring an additional 153,858 shares during the last quarter. BlackRock Inc. bought a new stake in Neonc Technologies during the 2nd quarter worth about $815,000. Bank of America Corp DE acquired a new position in shares of Neonc Technologies during the 2nd quarter worth about $1,017,000. Finally, Global Retirement Partners LLC bought a new position in shares of Neonc Technologies in the 2nd quarter valued at about $126,000.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NTHI. Alliance Global Partners began coverage on Neonc Technologies in a research report on Tuesday, May 19th. They set a “buy” rating and a $13.00 price target on the stock. BTIG Research reiterated a “buy” rating and issued a $15.00 price objective on shares of Neonc Technologies in a research report on Tuesday, September 8th. Wall Street Zen cut Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings upgraded shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 31st. Finally, Maxim Group assumed coverage on shares of Neonc Technologies in a research note on Monday, May 18th. They issued a “buy” rating and a $20.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $16.00.

Neonc Technologies News Roundup

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
• Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
• Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
• Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.